The Cancer Letter

Inside information on cancer research and drug development

In Brief

Laura Brod named CEO of GeneSegues Therapeutics

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

LAURA BROD was named CEO of GeneSegues Therapeutics. Brod is an at-large member of the University of Minnesota Board of Regents and is chair of the university’s Audit Committee. She was a member of the Minnesota House of Representatives from 2002 to 2010, during which time she served as assistant majority leader.

GeneSegues is based in Minneapolis and develops DNA and RNAi cancer therapeutics using sub-50 nanometer nanocapsule technology, including GS-10, for the treatment of a range of solid tumor cancers including head and neck, prostate and breast, as well as their related metastases.

Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Moving from mandate to mission: Community outreach and engagement at NCI-designated cancer centers
“COE is broken.”

Acting Director Dr. Krzysztof Ptak’s words reverberated throughout the meeting room—and the heads of several of us—during the National Cancer Institute’s Office of Cancer Centers update on the final day of the 2024 Association of American Cancer Institutes/Cancer Center Administrators Forum Annual Meeting in Chicago.
By Monica L. Baskin, Nadine J. Barrett, Kim F. Rhoads, Hayley S. Thompson, Kimlin Tam Ashing, Folakemi T. Odedina and Vanessa B. Sheppard

Art exhibit at University of Miami Sylvester bridges North and South America

“Bridge to Bahia” exhibit.Source: Sylvester Comprehensive Cancer CenterKaren Estrada, a survivor of acute myeloid leukemia, used visual art to communicate with her two boys while undergoing a bone marrow transplant at Sylvester Comprehensive Cancer Center. Because Estrada’s treatment required isolation, and her young children could not yet read and write, she sought out other creative vessels to foster closeness between them.
By Claire Marie Porter
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account